Status:
COMPLETED
Pneumococcal Vaccines in Patients With Asthma
Lead Sponsor:
Mayo Clinic
Conditions:
Asthma
Eligibility:
All Genders
19-64 years
Phase:
PHASE4
Brief Summary
Investigators are assessing if patients with asthma respond better to the Pneumovax vaccine if they are given Prevnar initially.
Detailed Description
Patients will be randomized into either PCV13 and PPSV23 (Experimental) or PPSV23 alone (Active comparator). At the Week 0 time point, the patients will receive either PCV13 (Experimental) or PPSV23 (...
Eligibility Criteria
Inclusion
- \- Diagnosis of asthma
Exclusion
- Research exemption requested
- History of PCV-13 vaccination
- History of cochlear implant
- Cerebrospinal Fluid (CSF) leak
- Congestive Heart Failure (CHF)
- Diabetes Mellitus (DM)
- Chronic Kidney Disease (CKD)
- Human Immunodeficiency Virus (HIV)
- Common Variable Immune Deficiency (CVID)
- Patients who have received the PPSV23 vaccine in the last 5 years
- Women who are pregnant will also be excluded from the study by performing 2 point of care urine pregnancy tests ( prior to vaccinations)
Key Trial Info
Start Date :
October 1 2017
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 25 2020
Estimated Enrollment :
17 Patients enrolled
Trial Details
Trial ID
NCT03260790
Start Date
October 1 2017
End Date
December 25 2020
Last Update
November 5 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Mayo Clinic in Rochester
Rochester, Minnesota, United States, 55905